摘要
高危非致残性缺血性脑血管事件(high risk non-disabling ischemic cerebrovascular events,HR-NICE)具有发病率高、复发率高等特点,国内外指南均建议对HR-NICE人群进行快速评估、早期干预以及建立专病管理系统等综合管理。同时在治疗方面,多项研究探讨了不同抗血小板药物治疗HRNICE人群及针对不同病因的患者采用抗凝或溶栓治疗的有效性及安全性。本文就高危非致残性缺血性脑血管事件的管理和治疗的循证医学证据作一简要综述。
The incidence and recurrence rate of high risk of disabling ischemic cerebrovascular events（HR-NICE） are high.The guidelines of both home and abroad suggest that the early comprehensive evaluation,intervention and establishing NICE management system will obtain great benefit.Several studies have revealed the efficacy and safety of antiplatelet medication,and choosing anticoagulation or thrombolysis treatment according to different cause,which may improve the prognosis.This article briefly reviews the evidence-based medicine in management of HR-NICE.
作者
马琳
陈玮琪
荆京
王拥军
王伊龙
MA Lin;CHEN Wei-Qi;JING Jing;WANG Yong-Jun;WANG Yi-Long.(Neurology Central, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China, China National Clinical Research Center for Neurological Diseases, Beijing 100050, China)
出处
《中国卒中杂志》
2018年第5期483-488,共6页
Chinese Journal of Stroke
关键词
高危非致残性脑血管事件
综合管理系统
抗栓
二级预防
溶栓
High risk non-disabling ischemic cerebrovascular events
Comprehensive management system
Antithrombotic therapy
Secondary prevention
Thrombolysis
